

Review

Open Access



# Long-term survival of robotic lobectomy for non-small cell lung cancer: a literature review

Sara Ricciardi<sup>1</sup>, Federico Davini<sup>2</sup>, Carmelina C. Zirafa<sup>2</sup>, Gaetano Romano<sup>2</sup>, Franca M. A. Melfi<sup>2</sup>

<sup>1</sup>Division of Thoracic Surgery, Department of Surgical, Medical, Molecular, Pathology and Critical Care, University Hospital of Pisa, Pisa 56124, Italy.

<sup>2</sup>Multispecialty Centre for Surgery, Minimally Invasive and Robotic Thoracic Surgery, University Hospital of Pisa, Pisa 56124, Italy.

**Correspondence to:** Dr. Sara Ricciardi, Division of Thoracic Surgery, Department of Surgical, Medical, Molecular, Pathology and Critical Care, University Hospital of Pisa, Via Paradisa 2, Pisa 56124, Italy. E-mail: ricciardi.sara87@gmail.com

**How to cite this article:** Ricciardi S, Davini F, Zirafa CC, Romano G, Melfi FMA. Long-term survival of robotic lobectomy for non-small cell lung cancer: a literature review. *Mini-invasive Surg* 2020;4:1. <http://dx.doi.org/10.20517/2574-1225.2019.50>

**Received:** 8 Nov 2019 **First Decision:** 27 Nov 2019 **Revised:** 9 Dec 2019 **Accepted:** 20 Dec 2019 **Published:** 6 Jan 2020

**Science Editor:** Valérie Lacroix **Copy Editor:** Jing-Wen Zhang **Production Editor:** Tian Zhang

## Abstract

Even though robotic-assisted surgery is increasingly used for resection of non-small cell lung cancer (NSCLC), data on long-term oncologic outcomes of robotic surgery are still not well defined. The primary endpoint of this review is to analyse the long-term results of robotic lobectomy in NSCLC patients. A systematic research was performed using the PubMed database. Articles published from January 2008 to January 2019 were included. We excluded studies that did not provide results for the long-term outcomes of robotic lobectomy, studies that had fewer than 50 cases and ones that focused on results of sub-lobar resections. Therefore, ten eligible studies were included in this analysis. In total, 2873 patients, with a mean age ranging between 66 and 68 years, who underwent robotic lobectomy for NSCLC, were analysed. Most patients (81%) had early-stage disease. The five-year overall survival for stage I disease fluctuated between 77% and 100%. The five-year disease-free survival was reported to be near 73%. We can conclude that robotic assisted lobectomy is an effective minimally-invasive procedure for lung resection. The current literature shows that robotic lobectomy is associated with long-term survival and lasting disease-free survival, equivalent to those reached by video-assisted thoracic surgery and open approach.

**Keywords:** Non-small cell lung cancer, robotic surgery, robotic lobectomy, long-term outcome, minimally invasive surgery

## INTRODUCTION

Surgical resection of non-small-cell lung cancer (NSCLC) is the preferred local treatment modality for operable disease and lobectomy remains the gold standard treatment in early-stage lung cancer<sup>[1]</sup>. Thanks



© The Author(s) 2020. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



to the technical and technological improvements achieved during the decades, the surgical approach has moved from open procedures to minimally invasive surgery (MIS). MIS [including video-assisted thoracic surgery (VATS) and robot-assisted surgery] has become the preferred approach in patients with no contraindications (anatomic or surgical), given that the less invasive approach does not compromise the oncologic cancer outcomes and is associated with better short-term results compared to thoracotomy<sup>[2]</sup>.

Regardless of the approach, the oncologic principles remain unchanged: the achievement of negative margins (R0 resection) and a systematic lymph node dissection; the open approach for lobectomy remains the cornerstone with which the results of the other techniques are compared.

Recent data have reported an important increase in VATS and robotic lobectomy versus open procedures and several studies have shown that MIS lobectomy results in comparable oncologic outcomes to those of open approach<sup>[3,4]</sup>. However, Level 1 evidence does not exist and data on long-term outcomes for NSCLC patients treated with robotic approach are still lacking<sup>[5]</sup>.

The aim of this review is to analyse the literature concerning the long-term survival of robotic lung lobectomy.

## METHODS

A literature review was conducted by searching PubMed in July 2019, using the search terms: (“lung cancer” OR “lung tumour” OR “lung neoplasm” OR “NSCLC”) AND (“robotic” OR “robot assisted” OR “da Vinci” OR “daVinci”) AND [“analysis, survival” (MESH TERMS)].

Inclusion criteria were: (1) the paper described robotic-assisted lobectomy; and (2) the study was a randomised controlled trial, meta-analysis or single centre/multicentre database study recording on robotic lobectomy.

Exclusion criteria were: (1) the study did not provide results for the long-term outcomes of robotic lobectomy; (2) the study focused on results of sub-lobar resections; and (3) the study included fewer than 50 cases.

After language restriction (English), applying inclusion and exclusion criteria and eliminating duplicate papers, ten studies were selected for this analysis, all reporting robotic lung lobectomy for NSCLC [Figure 1].

## RESULTS


Six retrospective, observational single centre studies, three retrospective multicentre studies and one prospective cohort study published between 2008 and January 2019 were included in this analysis [Table 1]. In total, 2873 patients, with a mean age ranging between 66 and 68 years, who underwent robotic lobectomy for NSCLC, were analysed.

The majority of patients (81%) had early-stage disease [1892 stage I (66%), 443 stage II (15%)] and only a few of them had advanced or metastatic disease [507 stage III (18%), 31 stage IV (1%)].

### Short-term outcomes

The mean length of stay reported was 4.5 days (ranging between 3 and 8 days), the mean conversion rate was 8.4% (ranging between 0% and 9.8%) and the mean post-operative 30-day mortality was 0.25% (ranging between 0% and 4.9%).

The mean rates of reported overall complications and major complications were 25.4% (ranging between 9.52% and 66.4%) and 5.85% (ranging between 2.4% and 10.3%), respectively [Table 1].



**Figure 1.** We present graphically our searching strategy. RCT: randomized control trial

### Mid- and long-term outcomes

The mid- and long-term outcomes of 2850 patients were analysed, with a survival time analysis ranging between two years and five years. Seven studies showed the survival of patients who underwent robotic surgery in a single centre with a follow-up ranging between 13.3 and 40.3 months. The studies were inhomogeneous for survival time analysis (two-, three- or five-year results) and patients' stage (only stage I analysis or multiple stage data) [Table 2].

Toosi *et al.*<sup>[6]</sup> analysed 249 patients who underwent robotic lobectomy and showed a mean operative-time, conversion rate and rates of perioperative outcomes comparable to those of VATS and open surgery. The primary endpoint of this study was the evaluation of the effectiveness of lymphadenectomy (LN) by robotic approach and the authors revealed that LN staging with robotic surgery was comparable to or better than that obtained with conventional VATS and open approach. Moreover, the authors showed an overall survival (OS) comparable with that described in the literature, but the survival analysis was limited by the short mean follow-up time (18 months).

The aim of the study published by Yang *et al.*<sup>[7]</sup> was to compare the long-term outcomes [OS and disease-free survival (DFS)] of three cohorts (robotic, VATS and open) of clinical stage I NSCLC patients matched by propensity score. The authors stated that MIS lobectomy for clinical stage I NSCLC guarantees comparable long-term survival as thoracotomy and was associated with shorter hospitalisation. The five-year OS and DFS for the robotic group were 77.6% and 72.7%, respectively, and 13.5% (25/184) patients experimented recurrences.

**Table 1. Short-term outcome of NSCLC treated by Robotic approach**

Ref.	Year	Number of patients	Type of study	Conversion rate	n of resected lymph nodes or n of station	Upstaging	Hospital stay (days)	Complications	Mortality	
									30 days	90 days
Toosi <i>et al.</i> <sup>[6]</sup>	2016	249	Retrospective single centre	22 (8.8%)	13.9 ± 0.4 nodes (range 1-37)	26.9%	5	90 (36.1%)	6 (2.4%)	
Veronesi <i>et al.</i> <sup>[14]</sup>	2018	210	Retrospective multicentre	22 (9.9%)	15.4 nodes (SD 7.9)	NA	5.3	148 (66.4%) Grade III-IV 23 (10.3%)	4/209 (1.9%)	8/198 (4%)
Yang <i>et al.</i> <sup>[7]</sup>	2017	172	Prospective single centre	16 (9%)	5 stations (range 0-8)	NA	4	51 (29.7%)	0	
Lee <i>et al.</i> <sup>[8]</sup>	2015	53	Retrospective single centre	1 (1.9%)	17 nodes (range 4-40)	13.2%	3	6 (9.52%)	0	
Park <i>et al.</i> <sup>[13]</sup>	2011	325	Retrospective multicentre	27 (8%)	5 stations (range 2-8)	24%	5	82 (25.2%) Major 12 (3.7%)	1 (0.3%)	
Gharagozloo <i>et al.</i> <sup>[9]</sup>	2008	54	Retrospective single centre	0	NA	16%	4	14 (22%)	3 (4.9%)	
Cheufou <i>et al.</i> <sup>[10]</sup>	2019	64	Retrospective single centre	6 (9.4%)	13.9 nodes (SD 6.5)	12.9%	8.3/7.9		0%	
Cerfolio <i>et al.</i> <sup>[15]</sup>	2018	1321	Retrospective multicentre	116 (9%)	19 nodes (range 11-42)	NA	3	24% Major 8%	0.2%	0.5%
Casiraghi <i>et al.</i> <sup>[11]</sup>	2019	307	Retrospective single centre	22 (6.5%)	15 nodes (range 1-55)	17.6%	5	87 (25.7%) Major 8 (2.4%)	0	0.3%
Zirafa <i>et al.</i> <sup>[12]</sup>	2019	212	Retrospective single centre	9 (4.2%)	17.4 nodes (range 7-37)	NA	3.6	54 (25.5%)	1 (0.4%)	

NSCLC: non-small-cell lung cancer; NA: not assessed

Another comparative study was the one by Lee *et al.*<sup>[8]</sup> The authors retrospectively analysed clinically node negative NSCLC patients who underwent VATS ( $n = 158$ ) or robotic ( $n = 53$ ) lobectomy showing a similar rate of nodal upstaging and similar DFS and OS between the two groups. In the robotic cohort with a mean follow-up of 13.3 months, the OS and DFS were 95% and 93%, respectively. They reported three (5.6%) cancer recurrences (all distant). One of the first studies which reported long-term outcomes of robotic surgery was published in 2008. With a follow-up of 28 months, Gharagozloo *et al.*<sup>[9]</sup> reported an OS of 100% and a DFS of 93% in a cohort of stage I and II NSCLC patients. No recurrences occurred.

A recent study conducted by Cheufou *et al.*<sup>[10]</sup> reported data on 64 patients who underwent robotic lobectomy for lung cancer. Their results showed a two-year survival rate of 83% with a rate of nodal upstaging of 12.9%.

Analyses of larger groups of patients were performed by Casiraghi *et al.*<sup>[11]</sup> and Zirafa *et al.*<sup>[12]</sup> Casiraghi *et al.*<sup>[11]</sup> reported data on 307 lobectomies, 29 segmentectomies and 3 pneumonectomies performed by robotic approach in NSCLC patients (stage IA-III A). The five-year OS of the lobectomy cohort was 89.1% with a DFS of 72.8%. There were 58 recurrences: 16 local (ipsilateral to the operated chest), 27 regional (contralateral) and 15 distant.

Zirafa *et al.*<sup>[12]</sup> analysed 212 patients who underwent robotic lobectomy ( $n = 211$ ) and bilobectomy ( $n = 1$ ) for NSCLC (stages IA-IV). With a mean follow-up of 40.3 months, they reported a five-year survival of 98.5% (stage I), 93.7% (stage II), 73.1% (stage III) and 0% (stage IV). The overall DFS was 66.3 months. Overall, 12.7% of loco-regional relapse and 10.9% of distant recurrence were observed.

Three retrospective multicentre studies were also included in this review. The first was conducted by Park and examined data on 325 patients who underwent robotic lobectomies in three high volume centres: 123 patients in New York, 82 in Milan and 120 in Pisa. The majority of the patients (76%, 248/325) were pathologic stage I (176 stage IA and 72 stage IB). Overall one- and five-year survival for the group was 98% and 80%, respectively. Twenty-five patients died of their disease. At a mean follow-up of 27 months, the

**Table 2. Mid- and Long-term outcomes of NSCLC treated by Robotic approach**

Ref.	Year	Number of patients	Type of study	Intervention	Follow-up (months)	Survival time analysis	Overall survival				DFS
							pStage I	pStage II	pStage III	pStage IV	
Toosi <i>et al.</i> <sup>[6]</sup>	2016	249	Retrospective single centre	Lobectomy	18	3-year	75%	73%	44%	0%	/
Veronesi <i>et al.</i> <sup>[14]</sup>	2018	210	Retrospective multicentre	Lobectomy	18	3-year	/	/	61.2%	/	37.7%
Yang <i>et al.</i> <sup>[14]</sup>	2017	172	Prospective single centre	Lobectomy	39.8	5-year	77.6%	/	/	/	72.7%
Lee <i>et al.</i> <sup>[8]</sup>	2015	53	Retrospective single centre	Lobectomy	13.3	2-year		95%		/	93%
Park <i>et al.</i> <sup>[13]</sup>	2011	325	Retrospective multicentre	Lobectomy	27	3-year	97% (IA), 88% (IB)	72%	43%	/	90%
Gharagozloo <i>et al.</i> <sup>[9]</sup>	2008	54	Retrospective single centre	Lobectomy	28	2-year	100%	100%	/	/	93%
Cheufou <i>et al.</i> <sup>[10]</sup>	2018	64	Retrospective single centre	Lobectomy	/	2-year		83%		/	/
Cerfolio <i>et al.</i> <sup>[15]</sup>	2018	1321	Retrospective multicentre	Lobectomy	30	5-year	83% (IA), 77% (IB)	68% (IIA), 70% (IIB)	62% (IIIA), 31% (IIIB)	54%	Mean DFS: 16 months
Casiraghi <i>et al.</i> <sup>[11]</sup>	2019	307	Retrospective single centre	Lobectomy	28.8	5-year		89.1%		/	72.8%
Zirafa <i>et al.</i> <sup>[12]</sup>	2019	212	Retrospective single centre	211 Lobectomy 1 Bilobectomy	40.3	5-year	98.5%	93.7%	73.1%	0%	Mean DFS: 66.3 months

DFS: disease free survival; NSCLC: non-small-cell lung cancer

recurrence rate was 10% (32/325). Most recurrences (72%) were distant (17 distant only; 6 locoregional + distant), and 28% (9/32) were locoregional only<sup>[13]</sup>.

The retrospective multicentre (seven centres) study led by Veronesi *et al.*<sup>[14]</sup> analysed 223 patients with NSCLC or carcinoid, with pathological (post-surgical) N2 disease (Stage IIIA) treated by robot assisted resection with curative intent, before or after chemotherapy or chemoradiation therapy. The study included 34 patients who underwent resection after induction therapies. With a mean follow-up of 18 months, mean survival for the 210 NSCLC patients (13 carcinoids) was 51 months, with three-year OS estimated at 61.2%. Twenty-five per cent of patients (56 cases) had distant relapse and 16.6% had local or lung recurrence.

Cerfolio *et al.*<sup>[15]</sup> reported the largest series of robotic lobectomy for NSCLC in four high volume centres. The authors analysed short- and long-term outcomes of 1339 and 1321 patients, respectively. Approximately 50% of patients had stage IA disease (672/1339). With a mean follow-up of 30 months (ranging between 1 and 154 months), the five-year stage-specific survival was: 83% for stage IA, 77% for stage IB, 68% for stage IIA, 70% for IIB, 62% for stage IIIA and 31% for stage IIIB. The recurrence rate was 15% (distant) and 3% (local).

## CONCLUSIONS

Robotic approach for lobectomy is one of the newest evolutions in MIS for NSCLC; however, long-term data on its oncologic efficacy are still limited. For this purpose, in this review, we have analysed ten studies, both monocentric and multicentric, to examine oncologic outcomes of patients who underwent robotic lobectomy.

Concerning short-term results, the robotic surgery has shown several promising results such as conversion rates to thoracotomy, transfusions rate, length of stay and readmission rates compared with VATS. A propensity-matched analysis conducted by Oh *et al.*<sup>[5]</sup> comparing open lobectomy and robotic lobectomy showed a lower postoperative complication rate, lower mortality rate and shorter hospital stay in the robotic cohort.

The conversion rate exposed in the present review ranges between 0% and 9.8%, comparable to that reported in the literature and lower than that of VATS<sup>[16-18]</sup>. Only one study reported a higher conversion

**Table 3. Stage specific overall survival according to the eighth edition of TNM**

Stage	Two-year survival	Five-year survival
IA1	97%	92%
IA2	94%	83%
IA3	90%	77%
IB	87%	68%
IIA	79%	60%
IIB	72%	53%
IIIA	55%	36%
IIIB	44%	26%
IIIC	24%	13%
IVA	23%	10%
IVB	10%	0%

rate in patients who underwent surgery after induction therapies (15% vs. 9.9%); however, this study showed the feasibility and safety of robotic approach even after neoadjuvant chemo-radiotherapy<sup>[14]</sup>.

The 30-day mortality rate of the entire population examined in this review is 0.25% (range 0%-4.9%). According to a recent meta-analysis conducted by O'Sullivan *et al.*<sup>[19]</sup>, the mortality rate is lower for patients who underwent robotic surgery compared to VATS or Open approaches with an overall protective effect of robotic over thoracotomy [OR: 0.53, 95%CI: 0.33-0.85 ( $P = 0.008$ )] and over VATS [OR: 0.61, 95%CI: 0.45-0.83 ( $P < 0.001$ )]. Notwithstanding these results should be thoughtfully considered, given that a possible selection bias in robotic cohort may have occurred, data on short-term outcomes of robotic surgery are very interesting.

Analysing the long-term results, the overall and stage-specific survival of robotic lobectomy are consistent with data reported by Goldstraw *et al.*<sup>[20]</sup>, which were mainly obtained by open surgery [Table 3].

According to the largest multicentre series of robotic lobectomy analyses by Cerfolio *et al.*<sup>[15]</sup>, which also included many other examined cohorts, the OS of patients who had completely resected NSCLC via robotic lobectomy is favourable compared to open surgery. One possible explanation proposed by the authors is a reduction of immunocompromised state after MIS surgery.

Moreover, the authors stated that DFS of robotic cohort is promising, especially in case of N2 disease. This is probably due to the easier and more precise dissection of lymph node during robotic surgery, which also leads to superior upstaging compared to VATS, improved staging and greater chance to undergo adjuvant chemotherapy<sup>[21]</sup>.

Our review reports good short- and long-term outcomes after robotic lobectomy for NSCLC, which combines the benefits of MIS with the accuracy of open surgery in stage-assessment, showing an overall and stage-specific OS comparable with that reported by IASLC database.

## DECLARATIONS

### Acknowledgments

The Authors thank Teresa Hung Key for linguistic accuracy checking.

### Authors' contributions

Conception and design, collection and assembly of data, data analysis and interpretation: Ricciardi S

Administrative support: Melfi FMA, Davini F

Provision of study materials or patients: Davini F, Romano G, Zirafa CC



Manuscript writing and final approval of manuscript: Ricciardi S, Davini F, Zirafa CC, Romano G, Melfi FMA

#### **Availability of data and materials**

Not applicable.

#### **Financial support and sponsorship**

None.

#### **Conflicts of interest**

Prof. Melfi is an official proctor for Intuitive Surgical. Drs. Davini, Ricciardi, Zirafa and Romano have no conflict of interest or financial ties to disclose.

#### **Ethical approval and consent to participate**

Not applicable.

#### **Consent for publication**

Not applicable.

#### **Copyright**

© The Author(s) 2020.

#### **REFERENCES**

1. NCCN guidelines, Version 5.2019, NSCLC. Available from [https://www.nccn.org/professionals/physician\\_gls/default.aspx](https://www.nccn.org/professionals/physician_gls/default.aspx) [Last accessed on 31 Dec 2019]
2. Paul S, Altorki NK, Sheng S, Lee PC, Harpole DH, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. *J Thorac Cardiovasc Surg* 2010;13:366-78.
3. Yang CJ, Kumar A, Klapper JA, Hartwig MG, Tong BC, et al. A national analysis of long-term survival following thoracoscopic versus open lobectomy for stage I non-small-cell lung cancer. *Ann Surg* 2019;269:163-71.
4. Berry MF, D'Amico TA, Onaitis MW, Kelsey CR. Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. *Ann Thorac Surg* 2014;98:197-202.
5. Oh DS, Reddy RM, Gorrepati ML, Mehendale S, Reed MF. Robotic-assisted, video-assisted thoracoscopic and open lobectomy: propensity matched analysis of recent premier data. *Ann Thorac Surg* 2017;104:1733-40.
6. Toosi K, Velez-Cubian FO, Glover J, Ng EP, Moodie CC, et al. Upstaging and survival after robotic-assisted thoracoscopic lobectomy for non-small cell lung cancer. *Surgery* 2016;160:1211-8.
7. Yang HX, Woo KM, Sima CS, Bains MS, Adusumilli PS, et al. Long-term survival based on the surgical approach to lobectomy for clinical stage I nonsmall cell lung cancer: comparison of robotic, video-assisted thoracic surgery, and thoracotomy lobectomy. *Ann Surg* 2017;265:431-7.
8. Lee BE, Shapiro M, Rutledge J, Korst RJ. Nodal upstaging in robotic and video assisted thoracic surgery lobectomy for clinical n0 lung cancer. *Ann Thorac Surg* 2015;100:229-33.
9. Gharagozloo F, Margolis M, Tempesta B. Robot-assisted thoracoscopic lobectomy for early-stage lung cancer. *Ann Thorac Surg* 2008;85:1880-5.
10. Cheufou DH, Mardanzai K, Ploenes T, Theegarten D, Stamatis G, et al. Effectiveness of robotic lobectomy-outcome and learning curve in a high volume center. *Thorac Cardiovasc Surg* 2019;67:573-7.
11. Casiraghi M, Galetta D, Borri A, Tessitore A, Romano R, et al. Ten years' experience in robotic-assisted thoracic surgery for early stage lung cancer. *Thorac Cardiovasc Surg* 2019;67:564-72.
12. Zirafa CC, Cavaliere I, Ricciardi S, Romano G, Davini F, et al. Long-term oncologic results for robotic major lung resection in non-small cell lung cancer (NSCLC) patients. *Surg Oncol* 2019;28:223-7.
13. Park BJ, Melfi F, Mussi A, Maisonneuve P, Spaggiari L, et al. Robotic lobectomy for non-small cell lung cancer (NSCLC): long-term oncologic results. *J Thorac Cardiovasc Surg* 2012;143:383-9.
14. Veronesi G, Park B, Cerfolio R, Dylewski M, Toker A, et al. Robotic resection of Stage III lung cancer: an international retrospective study. *Eur J Cardiothorac Surg* 2018;54:912-9.
15. Cerfolio R, Ghanim AF, Dylewski M, Veronesi G, Spaggiari L, et al. The long-term survival of robotic lobectomy for non-small cell lung cancer: a multi-institutional study. *J Thorac Cardiovasc Surg* 2018;155:778-86.
16. Takagi H, Yamamoto H, Goto SN, Matsui M, Umemoto T. Perioperative results of robotic lung lobectomy: summary of the literature. *Surg Endo* 2012;26:3697-9.

17. Yang CF, Sun Z, Speicher PJ, Saud SM, Gulack BC, et al. Use and outcomes of minimally invasive lobectomy for stage I non-small cell lung cancer in the National Cancer Data Base. *Ann Thorac Surg* 2016;101:1037-42.
18. Liang H, Liang W, Zhao L, Chen D, Zhang J, et al. Robotic versus video-assisted lobectomy/segmentectomy for lung cancer: a metaanalysis. *Ann Surg* 2018;268:254-9.
19. O'Sullivan KE, Kreaden US, Hebert AE, Eaton D, Redmond KC. A systematic review and meta-analysis of robotic versus open and video-assisted thoracoscopic surgery approaches for lobectomy. *Interact CardioVasc Thorac Surg* 2019;28:526-34.
20. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2016;11:39-51.
21. Wilson JL, Louie BE, Cerfolio RJ, Park BJ, Vallières E, et al. The prevalence of nodal upstaging during robotic lung resection in early stage non-small cell lung cancer. *Ann Thorac Surg* 2014;97:1901-7.